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Abstract
The spliceosome is a large ribonucleoprotein complex that catalyzes the removal of introns
from RNA polymerase II-transcribed RNAs. Spliceosome assembly occurs in a stepwise
manner through specific intermediates referred to as pre-spliceosome complexes E, A, B,
B* and C. It has been reported that small molecule inhibitors of the spliceosome that target
the SF3B1 protein component of complex A lead to the accumulation of cells in the G1 and
G2/M phases of the cell cycle. Here we performed a comprehensive flow cytometry analysis
of the effects of isoginkgetin (IGG), a natural compound that interferes with spliceosome
assembly at a later step, complex B formation. We found that IGG slowed cell cycle progres-
sion in multiple phases of the cell cycle (G1, S and G2) but not M phase. This pattern was
somewhat similar to but distinguishable from changes associated with an SF3B1 inhibitor,
pladienolide B (PB). Both drugs led to a significant decrease in nascent DNA synthesis in S
phase, indicative of an S phase arrest. However, IGG led to a much more prominent S
phase arrest than PB while PB exhibited a more pronounced G1 arrest that decreased the
proportion of cells in S phase as well. We also found that both drugs led to a comparable
decrease in the proportion of cells in M phase. This work indicates that spliceosome inhibi-
tors affect multiple phases of the cell cycle and that some of these effects vary in an agent-
specific manner despite the fact that they target splicing at similar stages of spliceosome
assembly.
Introduction
Pre-mRNA splicing is an essential step in the maturation of messenger RNAs (mRNAs)
required for the production of proteins in eukaryotic organisms [1]. The removal of introns
requires a combination of cis-acting elements and trans-acting factors. The cis-acting elements
include the 5’ splice site, the 3’ splice site, the branch point sequence and the polypyrimidine
tract. There are five trans-acting small nuclear RNAs (snRNAs: U1, U2, U4, U5 and U6) that
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are associated with many proteins that together form five protein complexes (U1, U2, U4, U5
and U6 snRNPs). Collectively, these snRNPs are required to assemble the major spliceosome
that catalyzes 99% of all pre-mRNA splicing [1, 2]. The snRNPs assemble on pre-mRNAs in a
sequential manner forming spliceosome complexes E, A, B, B and C, in succession. The pro-
cess is initiated when the U1 snRNP binds the 5’ splice site (E complex). Three proteins (SF1,
U2AF1 and U2AF2) bind the branch point sequence, the 3’ splice site and the polypyrimidine
tract of the intron, respectively before the U2 snRNP (including SF3B1) displaces SF1 and
binds to the branch point (A complex) [3, 4]. The B complex is then assembled through the
addition of the U4, U5 and U6 snRNPs and this complex is activated to permit catalytic activ-
ity. Splicing then proceeds through two transesterification reactions ligating exons and releas-
ing the intron [1–3].
There are many small molecule inhibitors of pre-mRNA splicing and many, if not all of
them, appear to exhibit anti-neoplastic activity in many cancer cell types [5–9]. Cell cycle anal-
ysis based on DNA content indicates that inhibition of pre-mRNA splicing leads to the accu-
mulation of cells with G1 and G2/M DNA content and a decrease in the proportion of cells in S
phase [10–12]. All of the drugs analyzed to date interact with the same protein target, SF3B1
and share a common mechanism of action [7, 10–14]. They interfere with U2 binding to the
branch point and thus complex A formation. It was unclear whether these alterations in cell
cycle distribution were caused by defects in SF3B1 specifically or if these changes are common
to all pre-mRNA splicing inhibitors.
Isoginkgetin (IGG) is a natural compound originally isolated from Ginkgo biloba trees that
inhibits splicing at a subsequent step in spliceosome assembly [15]. Although the precise target
of IGG remains unknown, it prevents the binding of U4/U5/U6 snRNPs to the pre-spliceo-
some complex, inhibiting B complex formation [15]. Therefore, IGG has a distinct mode of
action compared to the SF3B1 inhibitors like pladienolide B (PB). We sought to characterize
the effects of IGG on cell cycle distribution using PB for comparison in colon and ovarian can-
cer cells. We found that IGG slows cell cycle progression in multiple phases of the cell cycle
(G1, S and G2) with a decrease in the M phase population. S phase arrest was the predominant
effect detected following IGG treatment while G1 arrest was more prominent in PB-treated
cells. Therefore, the response of colon cancer cells to IGG was distinguishable from changes
associated with the SF3B1 inhibitor PB. This work provides important insight into the rela-
tionship between spliceosome inhibitors and cell cycle dysregulation and indicates that some
of these cell cycle alterations occur in an agent-specific manner.
Materials and methods
Cell culture and drug treatment
HCT116 colon cancer cells, a subline in which p53 was deleted by homologous recombination
(p53KO cells) and A2780 ovarian cancer cells were grown in McCoys media (Hyclone) supple-
mented with 12% serum in a 3 to 1 ratio of newborn calf serum (NBCS) (Gibco) to fetal bovine
serum (FBS) (Gibco) plus penicillin and streptomycin antibiotics (Hyclone). Cells were seeded
at a density of 5x105 cells per 6 cm dish 24 hours prior to treatment and they were treated in 3
ml of media containing dimethyl sulfoxide (DMSO), IGG or PB. IGG and PB were purchased
from EMD Millipore (Etobikoke, ON) while DMSO and colcemid were obtained from Sigma
Canada (Oakville, ON).
Cell cycle analysis
One parameter flow cytometric analysis of cell cycle distribution based on DNA content was
performed as previously described [16]. Briefly, cells were collected by following trypsin
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treatment. Cells were rinsed twice with phosphate buffered saline (PBS pH 7.4) and collected
by centrifugation. Pellets were resuspended in ice cold 70% ethanol and stored at -20˚C for a
minimum of 30 min. Cells were collected by centrifugation, rinsed twice in PBS and resus-
pended in 20 μg/ml propidium iodide (PI) in PBS with 10–50 μg/ml RNase A [16]. Cells were
stored at 4˚C for a minimum of 30 min. Fluorescence (FL2) was measured using a BD Accuri
C6 flow cytometer and cell cycle phase was estimated from histograms using Modfit 4.1 soft-
ware (Verity Software House, Topsham, ME).
Two parameter flow cytometric analysis was performed as previously described [17, 18].
Briefly, one hour prior to collection, the medium was replaced with fresh medium containing
30 uM 5’Bromo-2’deoxyuridine (BrdU) (Sigma). Cells were washed with PBS, detached with
trypsin and collected by centrifugation with two washes in PBS. Cells were then fixed in 70%
ethanol for a minimum of 1 hour at -20˚C. Fixed cells were washed in PBS and collected by
centrifugation before being resuspended in PBS with 50 μg/ml RNAse A and incubated for 30
minutes at 37˚C. Samples were centrifuged and the cells were resuspended in 0.1M HCl 0.7%
Triton X-100 and incubated on ice for 15 minutes. Cells were collected again, resuspended in
sterile H20, boiled for 15 minutes and immediately placed on ice for 15 minutes. One ml of
0.5% Tween 20 in PBS was added to the cell solution and cells were spun down. 0.5 ml of an
Alexa Fluor 488-conjugated anti-BrdU antibody (BD Biosciences) in PBS, 5% FBS and 0.5%
Tween 20 was added and incubated for 30 minutes. Cells were spun down and then resus-
pended in 30 μM propidium Iodide (PI) with RNase A. Samples were stored at 4˚C for a mini-
mum of 30 min prior to analysis of BrdU incorporation (FL1) and DNA content (FL2) using a
BD Accuri C6 benchtop flow cytometer and BD Accuri C6 software.
Detection of phosphorylated histone H3
Cell monolayers were rinsed with PBS and cells were collected with trypsin, as described
above. The cell pellets were resuspended in 4% formaldehyde and incubated for 10 minutes at
37˚C. The cells were then chilled on ice for 1 minute, permeabilized in 90% ice cold methanol,
and incubated on ice for 30 minutes. Cells were counted with a TC20 Automated Cell Counter
(BioRad) and 1x106 cells from each sample were stained. Cells were rinsed in 2–3 ml of incuba-
tion buffer (0.5% BSA in PBS) and collected by centrifugation. Cells were resuspended in
100 μl of Alexa Fluor 488-conjugated anti-phospho Histone H3 (Ser10) Antibody (EMD Milli-
pore cat#:06-570-AF488) diluted 1:50 in incubation buffer for 1 hour. Cells were washed in 2
ml incubation buffer and collected by centrifugation. Cells were resuspended in 200 μl of
30 μM PI stain for 30 minutes. Analysis of histone H3 phosphorylation (FL1) and DNA con-
tent (FL2) was performed using a BD Accuri C6 benchtop flow cytometer and BD Accuri C6
software.
Immunoblotting
Cell monolayers were rinsed with PBS and collected in 300 ul RIPA Buffer (Sigma). Samples
were sonicated and the protein was quantified using the Bio-Rad Protein Assay (Bio-Rad).
Equal amounts of protein were denatured in NuPAGE™ LDS Sample Buffer (Fisher Scientific)
with dithiothreitol (DTT), heated at 70˚C, loaded onto NuPAGE 4–12% Bis-Tris gels (Fisher
Scientific) and transferred to a nitrocellulose membrane (Bio-Rad). Transferred proteins were
visualized using 1 mg/ml Ponceau S Red in 1% glacial acetic acid. Membranes were blocked in
5% Milk in Tris Buffered Saline Tween (TBST) pH 8.0 (Tris Buffered Saline, 0.1% Tween 20)
for 1 hour. Membranes were incubated overnight at 4˚C in primary antibody in 0.5% Milk in
TBST pH 8.0. Membranes were washed 4x5 min in TBST and left in secondary antibody
(HRP-conjugated goat anti-mouse or goat anti-rabbit from Santa Cruz) for 1–3 hours.
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Membranes were washed 4x5 minutes in TBST then incubated for 5 minutes in 1 ml of Super
Signal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) and imaged with a
Fusion FX5 gel documentation system (Vilber Lourmat). Membranes were stripped using
Restore PLUS Western Blot Stripping Buffer (Fisher Scientific) and probed sequentially with
several antibodies. Primary antibodies included beta-actin (A2228, Sigma-Aldrich), Cyclin B
(554176, BD Pharmingen), Cyclin E (sc-198, Santa Cruz), and Cyclin A (Sc-751, Santa Cruz).
Results
Isoginkgetin treatment led to multiple changes in cell cycle progression
HCT116 colon cancer cells were exposed to various concentrations of IGG, up to the reported
IC50 (30 μM)[15] and cells were collected at either 8 or 24 hours for flow cytometric analysis
based on DNA content. The proportion of cells in the G1, S and G2/M phases of the cell cycle
was estimated using Modfit 4.1 software (Fig 1A). No significant alteration of cell cycle distri-
bution at either time point was detected (Fig 1B and 1C). This finding was perplexing given
previous analysis of splicing inhibitors [10–12, 19]. Therefore, we measured BrdU incorpo-
ration in IGG-treated HCT116 cells. Fewer IGG-treated cells incorporated BrdU compared to
untreated and DMSO-treated controls (Fig 1D). These results imply that the cytostatic effects
exerted by IGG were exerted roughly equally across all phases of the cell cycle.
We considered that the G1 and G2/M arrests reported in response to SF3B1 inhibitors were
detected using WiDr colon cancer cells and Chinese hamster ovary (CHO) cells, respectively
[10–12]. Both of these cell lines express mutant p53 [20, 21], an important cell cycle regulatory
protein, while HCT116 cells express wildtype p53 [22]. Therefore, we considered that p53-defi-
cient cells could respond differently to IGG treatment. IGG led to a similar decrease in BrdU
incorporation in an isogenic HCT116-derived p53 knockout (p53KO) cell line (Fig 1D) [22].
One parameter flow cytometric analysis based on DNA content indicated that there were
indeed differences in cell cycle alterations in the isogenic pairs of cell lines (Fig 1E and 1F).
Here we detected a significant increase in the proportion of cells with 4C DNA content (G2 or
M) with a corresponding decrease in the proportion of cells in S phase (Fig 1E). The decrease
in the proportion of cells in S phase was consistent with a p53-independent G1 arrest while the
sizeable accumulation of cells in G2 or M is indicative of an arrest in the G2 and/or M phases
of the cell cycle. G2 and M phases cannot be distinguished by DNA content alone. Importantly,
the changes observed in p53KO cells more closely paralleled those reported previously in other
p53-deficient cell lines [10–12].
IGG led to a decrease in the proportion of M phase cells
To distinguish between G2 and M phase arrest, we used two different methods. First, we exam-
ined the expression of cyclins E1, A2 and B1 because cyclin E1 is expressed through the G1 to S
phase transition, cyclin A2 is expressed in S phase and G2 phases predominantly while cyclin
B1 is the predominant mitotic cyclin (see [23] for review). In HCT116, there was little change
in cyclin E1 or cyclin A2 expression (Fig 2A). This correlated well with measured cell cycle dis-
tributions in G1, S and G2 phases, supporting the fact that cell cycle distribution is unaltered in
HCT116 cells in response to IGG treatment. Therefore, the cytostatic effects of IGG on
HCT116 proliferation (Fig 1C) are likely associated with a slowdown across multiple phases of
the cell cycle. The decrease in cyclin B1 suggested that the proportion of cells in M phase may
have decreased, however this population is usually small and would not affect the apparent cell
cycle distribution greatly.
In p53KO cells that had exhibited a loss of S phase and an increase in G2/M following IGG
treatment (recall Fig 1E); we detected a decrease in the expression of cyclins E1 and B1 with
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only very minor changes in cyclin A2 expression (Fig 2B). Decreased expression of cyclin E1
suggests that fewer cells were present in late G1 and early S phase. The expression of cyclin A2
remained unchanged and this was consistent with offsetting effects on S and G2 phases because
both of these populations of cells would be cyclin A2 positive. Once again, cyclin B1 expression
decreased in response to IGG while our positive control, the microtubule-depolymerizing
drug colcemid increased cyclin B1 expression, as expected (Fig 2B)[24]. Therefore, the large
Fig 1. Similar effects on cell growth but differences in cell cycle distribution in IGG treated HCT116 and p53KO cells. HCT116 and p53KO cells
were incubated in 15 μM IGG, 30 μM IGG or vehicle control for either 8 or 24 hours. One-parameter flow cytometric analysis of PI stained cells was used to
determine cell cycle distributions (G1, S and G2/M) based on DNA content, using Modfit 4.1 cell cycle analysis software. (A) Representative histograms are
presented for samples collected 24 hours following exposure to 30 μM IGG and its vehicle control. (B and C) The compiled cell cycle results from similar
analysis of HCT116 cells collected at 8 (B) and 24 (C) hours following treatment with the indicated concentration of IGG (open symbols) and the
corresponding vehicle controls (closed symbols). (D) HCT116 and p53KO (left and right panels, respectively) were incubated in growth medium alone
(circles), DMSO (triangles) or IGG (inverted triangles) along with BrdU for the indicated period. The proportion of cells incorporating BrdU at each time point
was estimated by flow cytometry. (E and F) p53KO cells were incubated in IGG for either 8 (D) or 24 hours (E) at the indicated concentration (open symbols)
or with an equivalent volume of DMSO (closed symbols). Each value in B through F represents the mean (+/- SEM) determined from a minimum of 3
independent experiments. *** indicates that the value is significant different (P<0.001) from controls (DMSO and no drug) by one way ANOVA followed by
Tukey multiple comparisons test.
https://doi.org/10.1371/journal.pone.0191178.g001
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accumulation of p53 KO cells with 4C DNA content (recall Fig 1E) is best accounted for by G2
accumulation and not M phase arrest.
Fig 2. Markers of M phase are decreased in response to IGG. (A) HCT116 cells were incubated in IGG for
24 hours. Protein lysates were collected and analyzed by immunoblot using antibodies raised against the
indicated proteins. (B) p53 KO cells were treated as described in (A) except that colcemid, a microtubule-
depolymerizing agent, was included in lane 6. HCT116 (C) and p53KO (D) cells were exposed to DMSO, IGG
or colcemid for 24 hours and the M phase-specific phosphorylation of histone H3 was detected using a
phosphospecific antibody coupled with flow cytometry. ‘M’ denotes the mitotic population. The proportion of
phospho-H3 positive cells was determined from 3 independent experiments (E and F). *, ** and *** denote
that the values were significantly different (P 0.05, 0.01, 0.001, respectively) by one way ANOVA followed by
a Tukey multiple comparisons test. Statistical analysis of colcemid, the positive control, was not included for
clarity.
https://doi.org/10.1371/journal.pone.0191178.g002
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To test this assertion further, we used flow cytometry to detect the proportion of cells carry-
ing the mitosis-specific phosphorylation of histone H3 on serine 10 (phospho-H3) [25]. The
proportion of phospho-H3 positive HCT116 and p53KO cells represented only a small fraction
of the total population in control samples and this small fraction decreased further in the pres-
ence of IGG (Fig 2C and 2D). In contrast to IGG, the M phase arrest associated with colcemid
treatment led to a remarkable increase in the proportion of phospho-H3 positive HCT116 and
p53KO cells (Fig 2C and 2D). Quantitative analysis of histograms derived from multiple inde-
pendent experiments indicated that the threefold decrease in phospho-H3 positive cells was
statistically significant (Fig 2E and 2F). Therefore, the accumulation of p53KO cells with 4C
DNA content did not result from a mitotic arrest but rather it is consistent with a G2 cell cycle
arrest.
IGG led to a pronounced reversible S phase arrest
We found no change in cell cycle distribution based on DNA content alone in IGG-treated
HCT116 cells despite inhibition of DNA replication (recall Fig 1A–1C). We performed two-
parameter flow cytometry analysis of BrdU incorporation and DNA content to better separate
early and late S phase cells from those cells with similar DNA content (G1 and G2, respec-
tively). Exposure of HCT116 cells to 30 μM IGG for 24 hours almost completely inhibited
BrdU incorporation (Fig 3A). This effect was slightly less pronounced in the p53KO cells
(Fig 3B). Nonetheless, the proportion of IGG-treated cells incorporating BrdU decreased sig-
nificantly in both cell lines, so that there was no longer a clear distinction between S and G2
phases (Fig 3C). The proportion of cells with S phase DNA content that incorporated BrdU
decreased significantly in the presence of IGG (cells above dashed line in Fig 3A and 3B). Even
among cells that had incorporated BrdU, there was a significant decrease in BrdU incorpo-
ration per cell (Fig 3D). Quantitation of cell cycle distribution using this more precise method
indicated that there was an overall decrease in the proportion of cells in S phase with a corre-
sponding increase in the G2 phase of the cell cycle in both cell lines (Fig 3E). However, the
proportion of cells in G2 is likely overestimated in Figs 1 and 3 because cells arrested in late
S phase cannot be distinguished from G2 and IGG clouded the S/G2 boundary. Overall, the
dominant effect detected both qualitatively (Fig 3A and 3B) and quantitatively (Fig 3C and
3D) was the remarkable decrease in DNA synthesis in the presence of IGG (Fig 3A and 3B).
This S phase arrest was reversible because removal of IGG permitted HCT116 cells to resume
DNA synthesis (Fig 3F). Taken together, IGG induced a pronounced S phase arrest in both
cell lines and this arrest was reversible.
These HCT116-derived cell lines are isogenic so it was possible that these cells were unique
in their S phase response to IGG exposure. Therefore, we also examined the response of A2780
ovarian cancer cells to IGG treatment. Consistent with the results in HCT116 and the p53KO
cell lines, replication decreased in A2780 cells treated with 30 μM IGG (Fig 4A). The propor-
tion of BrdU positive S phase cells decreased significantly (Fig 4B). Therefore, IGG induced an
S phase arrest in cell lines with distinct origin.
PB treatment leads to decreased replication and H3 phosphorylation
The predominant cell cycle alterations reported previously in response to spliceosome inhibi-
tion are the accumulation of cells with G1 and G2 DNA content with a decrease in the propor-
tion of cells with S phase DNA content [10–12]. However, previous cell cycle analysis was
limited to one-parameter flow cytometric analysis based on DNA content. Here we performed
two-parameter flow cytometric analysis of BrdU labelled cells to determine if a similar S phase
was induced by PB. Two prominent changes in S phase were noted in both HCT116 and
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p53KO cells. There was a large decrease in the proportion of BrdU positive cells, as observed
in response to IGG (Fig 5A–5C). However unlike IGG, the total number of cells with S phase
DNA content also decreased remarkably (Fig 5A and 5B). Therefore, the decrease in BrdU
positive cells wasn’t determined exclusively by decreased DNA replication in S phase cells.
Instead, decreased BrdU incorporation resulted from a decrease in the proportion of cells in S
phase. This is indicative of a prominent G1 arrest following PB but not IGG treatment. None-
theless, the small number of cells with S phase DNA content had incorporated less BrdU per
cell in the presence of PB, consistent with reduced replication in those cells that had escaped
the G1 arrest and entered S phase (Fig 5A and 5B). Therefore, the relative contribution of G1
Fig 3. IGG induces S phase arrest in HCT116 and p53KO cells. Two-parameter flow cytometry analysis of BrdU incorporation
and DNA content was performed following a 24-hour exposure of HCT116 (A) and p53 KO (B) cells to 30 μM IGG. (C) The
proportion of BrdU positive cells was determined and expressed relative to untreated controls. (D) Relative replication is an estimate
of the efficiency of DNA replication in the BrdU positive population of cells. (E) Cell cycle distribution of no drug- (ND), vehicle
control- (DMSO) and 30 IGG-treated cells was estimated from dot plots like those presented in A and B. (F) HCT116 cells were
exposed to either DMSO for 48 hours (DMSO) or IGG for 24 hours (dashed line) followed by either an additional 24 hours in IGG or
fresh medium with DMSO (REV). Data obtained from multiple experiments were expressed as the mean percentage of BrdU
positive cells. Each value in C-F represents the mean (+/- SEM) determined from 4, 4, 6 and 3 independent experiments,
respectively. In C and D, ** indicates that the values were significantly different (P < 0.01) by two way ANOVA followed by
Bonferroni post hoc tests. In E and F, * and ** denote that the value was significantly different (P < 0.05 or P< 0.01) by one-way
ANOVA followed by Tukey multiple comparisons test.
https://doi.org/10.1371/journal.pone.0191178.g003
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and S phase arrests to the overall cell cycle distribution was different in response to each of
these drugs.
Discussion
Pre-mRNA splicing is an essential step required to produce mature mRNAs so it is not entirely
surprising that perturbations of this processing step would have important consequences on
cell biology. Here we found that IGG treatment arrested cell cycle progression at several phases
of the cell cycle (G1, S and G2) in colon and ovarian cancer cell lines, although the relative con-
tribution of each is different among cell lines and drugs tested. Collectively, our results support
a model in which disruption of pre-mRNA splicing is linked to cell cycle regulation in multiple
phases of the cell cycle. The present work extends previous evidence linking pre-mRNA splic-
ing defects to alterations in mitotic cell division.
Fig 4. IGG induces S Phase arrest in A2780 ovarian cancer cells. (A) Two-parameter flow cytometric
analysis of BrdU incorporation and DNA content was performed following a 24-hour exposure of A2780 cells
to IGG. (B) The proportion of vehicle control (closed symbols) and IGG-treated (open symbols) BrdU positive
cells was determined. These values are expressed relative to untreated controls. Each value in B represents
the mean (+/- SEM) determined from 3 independent experiments. ** denotes that the value was significantly
different (P < 0.01) by two way ANOVA followed by Bonferroni post hoc tests.
https://doi.org/10.1371/journal.pone.0191178.g004
Fig 5. Effects of PB on S and M phases of the cell cycle. HCT116 and p53KO cells were exposed to either 0 or 25 nM PB for 24 hours.
HCT116 (A) and p53KO cells (B) were BrdU labelled for 1 hour prior to collection. BrdU incorporation was then assessed by two-parameter
flow cytometric analysis. (C) The proportion of cells incorporating BrdU was determined and this is expressed relative to untreated control
cells. (D) Phospho-H3 was detected as described in Fig 2. Each value in (C) and (D) represents the mean (+/- SEM) determined from 3
independent experiments. In (C), the mean values for both cell lines at 10 and 25 nM PB were significantly different from 1 by single sample
T test (P < 0.05). In (D), ** indicates that the values were significantly different (P<0.01) by Student T test.
https://doi.org/10.1371/journal.pone.0191178.g005
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The earliest evidence linking pre-mRNA splicing defects with cell cycle alterations stem
from early studies in yeast. Temperature sensitive cell division cycle mutants (cdc mutants)
isolated in Saccharomyces cerevisiae were instrumental in identifying proteins required for pro-
gression through the cell cycle [26, 27]. Strains carrying temperature sensitive mutations in the
CDC40/PRP17 gene accumulate intermediates of the splicing reaction and undergo G1/S and
mitotic arrest at the restrictive temperature [28–30]. Furthermore, 8 other splicing factors are
synthetic lethal with CDC40/PRP17: PRP8, PRP16, PRP22, SLU7, SLT11, SNR20, CLF1/SYF3,
SYF1 and SYF2 [30]. Like CDC40/PRP17, depletion of these proteins also yielded a variety of
mitotic defects [30] so mutations in a variety of pre-mRNA splicing factors inhibit cell cycle
progression.
There is also more recent genetic evidence to support a similar link between pre-mRNA
splicing and cell cycle progression in higher eukaryotes. In Drosophila melanogaster S2 cells,
142 genes were identified in a large scale screen for mitotic regulators and 13 of these were
splicing factors that, when depleted, gave rise to a defect in sister chromatid separation [31].
Notably, homologues of S. cerevisiae PRP17, PRP8 and SYF1 were among the splicing factors
identified [31]. Similarly, Kittler and coworkers screened a library of 5305 endoribonuclease-
prepared short interfering RNAs to identify genes required for cell cycle progression in HeLa
cells [32]. Thirty-seven genes were identified that were essential for cell division and 7 were
splicing factors. Once again depletion of these splicing factors gave rise to mitotic arrest with
abnormal spindle formation [32]. Collectively, genetic evidence links pre-mRNA splicing to
cell cycle progression, primarily through M phase defects.
Small molecule inhibitors of the spliceosome did not phenocopy mitotic defects in these
models. Inhibitors of SF3B1 reportedly induce the accumulation of cells in G1 and G2/M phases
with a depletion of the S phase population [10, 11, 19, 33]. Our observed G1 and G2 arrests fol-
lowing PB treatment were generally consistent with these earlier reports except that we did not
detect M phase arrest. Previous methodology did not allow assessment of M phase. We also
found that IGG led to a slowdown in all phases of the cell cycle except M phase. Thus, cell cycle
alterations associated with the small molecule inhibitors did not resemble the results obtained
following RNA interference or in genetic models of spliceosome dysfunction. In fact, the two
inhibitors assessed in the present work did not lead to identical changes in cell cycle kinetics.
Perhaps the most striking cell cycle phenotype identified here was the striking decrease in
DNA replication observed in response to IGG and PB. The overall decrease was the result of
the combined effects of G1 and S phase arrests. G1 arrest delays or prevents entry in to S phase,
inhibiting DNA synthesis and S phase arrest leads to decreased nascent DNA synthesis in S
phase. PB led primarily to a decrease in the proportion of cells in S phase due to G1 arrest. Yet
a small fraction of PB-treated cells had S phase DNA content but incorporated BrdU poorly.
In contrast, there was no decrease in the proportion of IGG-treated HCT116 cells in S phase.
Therefore, the inhibition of nascent DNA synthesis in these IGG-treated cells resulted in large
part from a pronounced S phase arrest.
Madrasin is a recently described splicing inhibitor that interferes with the transition from
complex A to B [19]. One-parameter flow cytometric analysis of the cellular response to
madrasin suggested that this drug leads to the accumulation of cells in S, G2 and M phase [19].
These authors did not perform two-flow cytometric analysis to determine if the accumulation
of cells in S phase was associated replication arrest. Nonetheless, they noted that nascent DNA
synthesis was inhibited using fluorescence microscopy of 5-ethynyl-20-deoxyuridine (EdU)
incorporation [19]. However, the inhibition of DNA synthesis did not correlate well with the
fraction of cells in S phase so it isn’t clear if madrasin decreased DNA synthesis through G1
and/or S. Nonetheless, our work coupled with this previous publication suggests spliceosome
inhibitors prevent normal DNA replication.
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Intriguingly, the only stage of the cell cycle for which we found no evidence of an arrest was
M phase. Instead, we found that both IGG and PB led to decreased phosphorylation of histone
H3 on serine 10. This specific phosphorylation is indicative of M phase [25]. Our positive con-
trol colcemid, a microtubule-depolymerizing drug that induces M phase arrest [24], led to a
pronounced accumulation of cells expressing phosphorylated H3 protein, as expected. The
decrease in M phase was simultaneously associated with decreased expression of the M phase
cyclin B1. Together, our results failed to support the existence of an M phase arrest following
chemical inhibition of pre-mRNA splicing and clearly distinguish the cellular responses to
spliceosome inhibitors from genetic models of spliceosome dysfunction in S. cerevisiae, D. mel-
anogaster and HeLa cells in which spindle defects and M phase arrest were the predominant
cell cycle related alterations [28–32].
Lastly, we detected subtle differences in the response of isogenic cell lines differing in p53
status. The p53KO cell line appeared to accumulate in G2 concomitant with a decrease in the
proportion of cells in S phase following IGG treatment (recall Fig 1E). However, the more
informative two-parameter flow cytometric method suggested that this increase in G2 in IGG-
treated p53KO cells was less pronounced than seen when analyzing DNA content alone. It is
likely that cell cycle analysis based on DNA content alone overestimated the G2 accumulation
because G2 phase was difficult to distinguish from late S phase in both cell lines due to the
arrest of cells in late S phase (recall Fig 3A and 3B). None of the changes in cell cycle distribu-
tion observed in response to IGG or PB fit the simple model of p53-dependent cell cycle arrest.
The p53 protein is a well-known tumour suppressor that functions as a sequence-specific tran-
scription factor [34]. The cyclin-dependent kinase inhibitor p21WAF1 is transcriptionally regu-
lated by p53 and increased p21WAF1 leads to G1 and G2 arrests in response to p53 activation
[22, 35, 36]. Here the IGG-induced G2 arrest may have been somewhat larger in the absence of
p53 but it displayed a similar S phase arrest and equivalent alterations in M phase.
At present, there is no mechanism that links splicing defects to cell cycle control. It may be
that pre-mRNA splicing inhibitors lead to decreased production of rate-limiting proteins
required for cell cycle progression. Alternatively, there may be specific splicing checkpoints
that detect the integrity of this mRNA processing step and respond appropriately. Future
efforts will be directed at determining how inhibition of spliceosome function leads to cell
cycle arrest in these various phases of the cell cycle, how p53 affects cell cycle alterations and
why these small molecule inhibitors of the spliceosome appear to interfere with the cell cycle
differently than RNA interference strategies.
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